SynthesisJournal of medical virology2022
Clinical characteristics and prognostic factors of myocarditis associated with the mRNA COVID-19 vaccine.
Synthesis in Journal of medical virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 4 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Myopericarditis After COVID-19 mRNA Vaccination Among Adolescents and Young Adults: A Systematic Review and Meta-analysis.JAMA pediatrics · 2023Pooled it
- Pooled it
- Global reports of myocarditis following COVID-19 vaccination: A systematic review and meta-analysis.Diabetes & metabolic syndrome · 2022Pooled it
- Clinical characteristics and prognostic factors of myocarditis associated with the mRNA COVID-19 vaccine.Journal of medical virology · 2022Pooled it
- From discovery through emergency use to the present: Safety evaluation of the COVID-19 mRNA-1273 (Moderna) vaccine.Human vaccines & immunotherapeutics · 2026Review
- Pre-existing Comorbidities as Potential Risk Modifiers for New-Onset Myocarditis and Pericarditis following mRNA COVID-19 Vaccination in Males Aged 18-30 in the United States: A Disproportionality Analysis using VAERS Spontaneous Reporting Data.Drugs - real world outcomes · 2026Article
- Evaluation of Cardiac Troponin Levels in Individuals Aged 12-30 Years Following mRNA-1273 Vaccination: Results From a Randomized Placebo-Controlled Trial.Open forum infectious diseases · 2026Article
- Evolution in the Diagnosis and Treatment of Myocarditis in Recent Years: State of the Art.Journal of clinical medicine · 2025Review
- COVID-19 and Myocarditis: Trends, Clinical Characteristics, and Future Directions.Journal of clinical medicine · 2025Review
- Cardiovascular Sequelae of the COVID-19 Vaccines.Cureus · 2025Review
- Current Status and Future Trends in Myocarditis Related to the COVID-19 Vaccines: A Visual and Bibliometric Analysis.Current vascular pharmacology · 2025Article
- Temporal evolution of electrocardiographic anomalies observed in a young woman after COVID-19 vaccine.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2025Article
- A Study on the Self-Reported Physician-Diagnosed Cardiac Complications Post mRNA Vaccination in Saudi Arabia.Cureus · 2024Article
- IL-1RA autoantibodies: insights into mechanisms and associated diseases.American journal of translational research · 2024Review
- Systematic review and meta-analysis of myocarditis and pericarditis in adolescents following COVID-19 BNT162b2 vaccination.NPJ vaccines · 2023Review
- Myocarditis or Pericarditis Events After BNT162b2 Vaccination in Individuals Aged 12 to 17 Years in Ontario, Canada.JAMA pediatrics · 2023Article
- The incidence and clinical characteristics of myocarditis and pericarditis following mRNA-based COVID-19 vaccination in Republic of Korea adolescents from July 2021 to September 2022.Osong public health and research perspectives · 2023Article
- Risk of Coronavirus Disease 2019 Messenger RNA Vaccination-Associated Myocarditis and Pericarditis - A Systematic Review of Population-Based Data.Risk management and healthcare policy · 2023Review
- Medium-term outcomes of myocarditis and pericarditis following BNT162b2 vaccination among adolescents in Hong Kong.Emerging microbes & infections · 2022Article
- Intricacies Affiliated With Post-COVID Vaccine Complications in Makkah Province, Saudi Arabia.Cureus · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 7 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To analyze the clinical presentation and outcomes of myocarditis after administration of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccine. Nine case series and 15 case reports (74 patients) of myocarditis after administration of the BNT162b2 or mRNA-1273 vaccine were reviewed from PubMed, Scopus, Embase, and Web of Science. We analyzed clinical manifestations, diagnostic findings, and outcomes. In addition, we performed a pooled analysis and investigated risk factors leading to admission to the intensive care unit and recovery with conservative care. Most patients were male (94.6%), and the median age (range) was 17.6 (14-70) years. Patients who received the BNT162b2 (n = 58, 78.4%) vaccine presented fewer systemic symptoms and left ventricular dysfunction than mRNA-1273 recipients. Although patients under 20 years experienced more fever and myalgia, they had better ejection fraction and less prominent myocardial inflammation in magnetic resonance imaging than older patients. The clinical course of all patients was favorable without mortality, and one-third of patients resolved with conservative care alone. Risk factor analyses revealed that patients with gastrointestinal symptoms required intensive care (odds ratio: 20.3, 95% confidence interval 1.90-217, p = 0.013). The risk of fatality in myocarditis subjected to mRNA vaccination seems to be low. However, patients with gastrointestinal symptoms received more intensive care, and a significant proportion of patients recovered with conservative management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.